Mechanistically, the superior antitumor effect of systemic delivery of Hiltonol may be due to the stimulation of MDA5 in bone marrow-derived immune cells and tumor vascular endothelial cells by Hiltonol, which leads to the production of type I IFN and T cell recruiting chemokines such as CXCL9/CXCL10, and the promotion of tumor T cell infiltration [289]. This evidence concerns the gene IFIH1 and neoplasm.